NCT07032077View on ClinicalTrials.gov

A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2027

Conditions

Solid Tumors

Interventions

DRUG

HRS-7058

HRS-7058 combimed with antitumor drugs

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY